CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Slated for Live Webcast at VirtualInvestorConferences.com

September 8, 2021 09:50:08

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), will be featured at the upcoming VirtualInvestorConferences.com. InMed president and CEO is scheduled to present a real-time, interactive presentations during the two-day conference; InMed’s presentation will start at 1:30 p.m. ET on Sept. 8, 2021. During the presentation Adams will provide an overview of the company’s recent highlights as well as answer questions from potential investors in real time. Company highlights include the announcement that it has increased the yield of its proprietary IntegraSyn(TM) rare cannabinoid manufacturing approach to 5 g/L, further improving the overall economics in advance of commercial-scale production and that it has signed a nonbinding letter of intent to acquire BayMedica, a private company that specializes in the manufacture and commercialization of rare cannabinoids. In addition, as part of a phase 2 clinical trial, InMed has filed clinical trial applications in several countries. Virtual Investor Conferences (“VIC”) has developed a reputation for being a leading proprietary investor conference series; VIC events provide an interactive forum for publicly traded companies to meet and present directly with investors.

To register for the event, visit https://cnw.fm/g2Lii

To view the full press release, visit https://cnw.fm/T0KhW

About InMed Pharmaceuticals Inc.

InMed is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”) and is developing IntegraSyn to produce pharmaceutical-grade cannabinoids. The company is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.